ArticlePulmonary circulation2023

SATISFY-JP, a phase II multicenter open-label study on Satralizumab, an anti-IL-6 receptor antibody, use for the treatment of pulmonary arterial hypertension in patients with an immune-responsive-phenotype: Study protocol.

Yuichi Tamura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.